Debate Grows Over Whether Israel Should Retain Access to EU Research Funding After 2027

A fresh debate is gaining traction in European policy circles over whether Israel should continue participating in the European Union’s flagship research and innovation programme beyond its current funding cycle, with advocates arguing that excluding the country would ultimately harm Europe’s own scientific and economic interests.

Israel has been an associate member of the EU’s Horizon research programme for decades, granting Israeli universities, startups, and research institutions access to billions of euros in collaborative funding alongside their European counterparts. The current Horizon Europe framework runs until 2027, and negotiations over the successor programme — expected to cover the period from 2028 to 2034 — are set to become a significant point of contention within European institutions.

Writing in a recent op-ed published by Euronews, commentator Carsten Ovens made the case that Israel’s continued inclusion in the European Research Area is not merely a diplomatic gesture but a strategic necessity for the continent. Ovens argued that Israel’s dense concentration of technology firms, leading universities, and research talent makes it one of Europe’s most valuable external partners in innovation, and that severing or limiting those ties would weaken Europe’s position in global competition with the United States and China.

Strategic Value vs. Political Pressure

The argument in favour of continued Israeli participation centres largely on economic and scientific grounds. Israel consistently ranks among the top performers within Horizon in terms of publications, patents, and cross-border research collaborations. Sectors including cybersecurity, agri-tech, medical devices, and artificial intelligence have all benefited from joint European-Israeli projects, according to reports from research policy organisations tracking programme outcomes.

However, the political landscape surrounding the question has shifted considerably. Since the outbreak of the conflict in Gaza in October 2023, a number of European universities and academic bodies have suspended bilateral agreements with Israeli institutions, and calls have grown in some quarters for the EU itself to reconsider the terms of Israel’s association agreement. Critics argue that continued unconditional access to EU funding sends a problematic political signal at a sensitive moment in international relations.

EU officials have so far maintained that scientific cooperation and political disputes are legally and institutionally separate matters, and that any changes to Israel’s associate membership status would require a formal review process involving member states. The European Commission has not publicly indicated any intention to alter the existing framework ahead of the 2027 deadline.

The coming years are likely to see intensifying lobbying on both sides of the debate. Pro-engagement voices, including those in the German liberal political tradition from which Ovens writes, stress that Europe’s long-term technological competitiveness depends on preserving open research partnerships with democracies beyond the continent’s borders. Opponents counter that the EU’s credibility as a values-based institution requires greater consistency between its funding decisions and its stated commitments on international law and human rights.

With formal negotiations over the post-2027 research framework expected to begin in earnest in the coming months, the question of Israel’s place in the European Research Area looks set to become one of the more politically charged dimensions of an otherwise technocratic budgetary process.